Dr Lal Pathlabs Q2 FY26 Earnings Analysis

Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹31.7K Cr

Price

1,887.1

Market Cap

₹31.7K Cr

P/E Ratio

56.3

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Dr Lal Pathlabs Q2 FY26 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Dr Lal Pathlabs share price analysis?

Dr Lal Pathlabs currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,652. Investors should review the full earnings analysis for detailed insights.

Is Dr Lal Pathlabs planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Healthcare Services this season

  • Syngene International Ltd (Q2 FY26)

    Syngene International Ltd Q2 FY26 quarterly results analysis. - Syngene expects continued revenue growth driven by strong momentum in Research Services, account

  • Rainbow Childrens Medicare Ltd (Q2 FY26)

    Rainbow Child. Q2 FY26 quarterly results analysis. - Revenue growth guidance remains in the late teens to around 20%, supported by bed additions and recent acqu

  • Vijaya Diagnostic Centre Ltd (Q2 FY26)

    Vijaya Diagnost. Q2 FY26 quarterly results analysis. - Vijaya Diagnostic targets consistent revenue growth of 15%+ annually, backed by about 13% volume growth.

  • Krsnaa Diagnostics Ltd (Q2 FY26)

    Krsnaa Diagnost. Q2 FY26 quarterly results analysis. - Volume growth currently subdued (~4-5%) compared to industry (~10%) due to suspension of some projects li